Caribou Biosciences, Inc.
CRBU
$0.79
$0.03264.30%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.08M | 2.02M | 3.46M | 2.43M | 3.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.08M | 2.02M | 3.46M | 2.43M | 3.56M |
| Cost of Revenue | 29.86M | 29.82M | 35.48M | 33.79M | 31.28M |
| Gross Profit | -27.79M | -27.80M | -32.02M | -31.36M | -27.72M |
| SG&A Expenses | 10.49M | 5.94M | 11.49M | 14.64M | 9.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.35M | 35.76M | 46.97M | 48.43M | 41.00M |
| Operating Income | -38.28M | -33.74M | -43.50M | -46.00M | -37.44M |
| Income Before Tax | -35.50M | -34.68M | -37.70M | -41.23M | -34.31M |
| Income Tax Expenses | -9.00K | -- | -- | -- | 193.00K |
| Earnings from Continuing Operations | -35.49M | -34.68M | -37.70M | -41.23M | -34.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.49M | -34.68M | -37.70M | -41.23M | -34.51M |
| EBIT | -38.28M | -33.74M | -43.50M | -46.00M | -37.44M |
| EBITDA | -37.09M | -32.56M | -42.65M | -45.29M | -36.70M |
| EPS Basic | -0.39 | -0.38 | -0.42 | -0.46 | -0.39 |
| Normalized Basic EPS | -0.24 | -0.21 | -0.26 | -0.29 | -0.24 |
| EPS Diluted | -0.39 | -0.38 | -0.42 | -0.46 | -0.39 |
| Normalized Diluted EPS | -0.24 | -0.21 | -0.26 | -0.29 | -0.24 |
| Average Basic Shares Outstanding | 91.16M | 90.46M | 90.34M | 89.30M | 88.43M |
| Average Diluted Shares Outstanding | 91.16M | 90.46M | 90.34M | 89.30M | 88.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
